Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.
Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma. We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use. This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.
Folk
J J
JJ
Department of Obstetrics and Gynecology, State University of New York, Health Science Center, Syracuse 13210, USA.
Mazur
M T
MT
Eddy
G L
GL
Musa
A G
AG
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000378:metabolism; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000378:metabolism; D005260:Female; D006801:Humans; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use
D013629:Tamoxifen